Ref: MHL/Sec&Legal/2021-22/75 Date: February 12, 2022

Τo,

Head, Listing Compliance Department BSE Limited

Phiroze Jeejeebhoy Towers Dalal Street, Mumbai - 400 001.

Scrip Code: 542650

Head, Listing Compliance Department National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1. G Block, Bandra -Kurla Complex, Bandra (East), Mumbai- 400051.

Scrip Symbol: METROPOLIS

Sub: Corrigendum - Limited Review Report on the Unaudited Consolidated Financial Results

of the Company for the quarter and nine months ended December 31, 2021.

Ref: Outcome of Board Meeting held on Friday, February 11, 2022

Dear Sir/Madam,

We refer to our letter dated February 11, 2022 submitting Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2021, Auditors' Limited Review Report and the requisite declaration on unmodified opinion (Reference no. MHL/Sec&Legal/2021-22/71)

There was a typographical error in the Limited Review Report for the quarter and nine months ended December 31, 2021 that inadvertently referred to Regulation 52(4) read with Regulation 63(2) in addition to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please find enclosed the correct Limited Review Report for the quarter and nine months ended December 31, 2021. We further state that there is no change in the revenue, profit before tax, profit and earnings per share (EPS) numbers of the Group reported in the Unaudited Consolidated Financial Results submitted to you on February 11, 2022.

You are requested to kindly take the above into consideration and on records.

Thanking you, Yours faithfully

For Metropolis Healthcare Limited

Simmi Singh Bisht **Head-Legal and Secretarial** Membership No. A23360

Encl. a/a



BLOOD TESTS • DIAGNOSTICS • WELLNESS

Metropolis Healthcare Limited

Global Reference Laboratory: 4th Floor, Commercial Building-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070.

BSR&Co.LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063, India Telephone: +91 22 6257 1000 Fax: +91 22 6257 1010

Limited Review Report on unaudited consolidated financial results of Metropolis Healthcare Limited for the quarter ended 31 December 2021 and year-to-date results for the period from 1 April 2021 to 31 December 2021 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Metropolis Healthcare Limited

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Metropolis Healthcare Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its joint venture for the quarter ended 31 December 2021 and year-to-date results for the period from 1 April 2021 to 31 December 2021 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
- 2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
 - We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
- 4. The Statement includes the results of the following entities mentioned in Annexure I to the Statement:
- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of two (2) subsidiaries included in the Statement, whose interim financial information reflects total revenues of Rs. 1,913 lakhs, total net profit after tax of Rs. 445 lakhs and total comprehensive income of Rs. 445 lakhs, for the quarter ended 31 December 2021 and for the period from 1 April 2021 to 31 December 2021 respectively, as considered in the unaudited consolidated financial results. These interim financial information have been reviewed by other auditor whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial information of six (6) subsidiaries which have not been reviewed, whose interim financial information reflects total revenues of Rs. 1,880 lakhs and Rs. 4,744 lakhs, total net profit after tax of Rs. 413 lakhs and Rs. 1,019 lakhs and total comprehensive income of Rs. 420 lakhs and Rs. 864 lakhs, for the quarter ended 31 December 2021 and for the period from 1 April 2021 to 31 December 2021 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**Chartered Accountants

Firm's Registration No.:101248W/W-100022

TARUN
KANAYALAL
KINGER
Digitally signed b
TARUN KANAYAL
KINGER
Date: 2022.02.11
22.02.43 +0530'

Tarun Kinger
Partner
Membership No.: 105003
UDIN:22105003ABHTWC2331

Mumbai 11 February 2022

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Sudharma Metropolis Health Services Private Limited	Subsidiary
2	Bokil Golwilkar Metropolis Healthcare Private Limited	Subsidiary
3	Raj Metropolis Healthcare Private Limited	Subsidiary
4	Desai Metropolis Health Services Private Limited	Subsidiary
5	R.V. Metropolis Diagnostics & Healthcare Centre Private Limited	Subsidiary
6	Micron Metropolis Healthcare Private Limited	Subsidiary
7	Dr. Patel Metropolis Healthcare Private Limited	Subsidiary
8	Lab One Metropolis Healthcare Services Private Limited	Subsidiary
9	Amins Pathology Laboratory Private Limited	Subsidiary
10	Ekopath Metropolis Lab Services Private Limited	Subsidiary
11	Dr. Ganesan's Hitech Diagnostics Centre Private Limited	Subsidiary w.e.f 22 October 2021
12	Centralab Healthcare Services Private Limited	Subsidiary w.e.f 22 October 2021
13	Metropolis Healthcare Lanka Private Limited	Subsidiary
14	Metropolis Healthcare (Mauritius) Limited	Subsidiary
15	Metropolis Star Lab Kenya Limited	Subsidiary
16	Metropolis Healthcare Ghana Limited	Subsidiary
17	Metropolis Bramser Lab Services (Mtius) Limited	Subsidiary
18	Metropolis Healthcare (Tanzania) Limited	Subsidiary
19	Metropolis Histoxpert Digital Services Private Limited	Subsidiary w.e.f 26 November 2021